[HTML][HTML] Aggressive prolactinoma
Aggressive prolactinoma (APRL) is a subgroup of aggressive pituitary tumors (accounting
for 10% of all hypophyseal neoplasia) which are defined by: invasion based on radiological …
for 10% of all hypophyseal neoplasia) which are defined by: invasion based on radiological …
[HTML][HTML] Update in pathogenesis, diagnosis, and therapy of prolactinoma
N Fukuhara, M Nishiyama, Y Iwasaki - Cancers, 2022 - mdpi.com
Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …
[HTML][HTML] Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature
Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …
[HTML][HTML] Prolactinoma: clinical characteristics, management and outcome
H Irfan, W Shafiq, AI Siddiqi, S Ashfaq, S Attaullah… - Cureus, 2022 - ncbi.nlm.nih.gov
Aim Prolactinoma, a prolactin (PRL) secreting functioning pituitary tumor, is the most
common of all pituitary adenomas (PA) accounting for 40-60% and dopamine agonists (DA) …
common of all pituitary adenomas (PA) accounting for 40-60% and dopamine agonists (DA) …
[HTML][HTML] The PRolaCT studies—a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma
IM Zandbergen, AH Zamanipoor Najafabadi… - Trials, 2021 - Springer
Background First-line treatment for prolactinomas is a medical treatment with dopamine
agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post …
agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post …
When to discontinue treatment of prolactinoma?
JAH Wass - Nature Clinical Practice Endocrinology & Metabolism, 2006 - nature.com
Prolactinomas are the most common hormone-secreting pituitary tumors. Treatment with
dopamine agonists can stabilize disease and recent evidence suggests that in many cases …
dopamine agonists can stabilize disease and recent evidence suggests that in many cases …
[HTML][HTML] Prolactinoma
RKR Yatavelli, K Bhusal - 2017 - europepmc.org
Objectives: Identify the common presentations of prolactinomas. Outline the evaluation of
prolactinomas. Review the management of prolactinomas. Explain the role of collaboration …
prolactinomas. Review the management of prolactinomas. Explain the role of collaboration …
What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
J Phillips, HE East, SE French, E Melcescu… - Hormones, 2012 - Springer
INTRODUCTION Malignant prolactinoma is an exceedingly rare endocrine tumor and
cannot be diagnosed on histological grounds alone. Similarly to other neuroendocrine …
cannot be diagnosed on histological grounds alone. Similarly to other neuroendocrine …